keep us under-perform
erratum correct valuat text cover reflect use blend
approach incorpor rel valu ep dcf
termin growth rate correct
bottom line updat model result
incorpor detail confer call follow call
compani main concern continu pressur humira sale
europ face direct biosimilar competit question
humira growth outlook us especi current us
price environ abil certain newer asset meet current
consensu expect also remain compani expect deliv
ep growth base midpoint guidanc rang
larg percentag result gross margin expans turn
driven roll humira royalti payment share repurchas
upcom regulatori decis risankizumab april upadacitinib
decemb commerci uptak product critic
understand compani abl off-set humira declin
upadacitinib intrigu compani commentari see
dose recommend rheumatoid arthriti wait see
full data dose indic see
product profil allow come close achiev
potenti sale compani previous suggest
notabl model updat along updat humira us ex-u
sale also lower estim orilissa rais
meaning hcv venclexta expens assumpt
gener line compani guidanc still well
guidanc oper margin current forecast
valuat risk target price remain maintain
under-perform rate ep estim chang
tp under-perform rate
deriv blend dcf use wacc
termin growth rate rel valuat ep
main risk call includ stronger-than-expect humira sale
and/or success diversif busi away humira
dividend yield provid support share current level
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
research-bas pharmaceut compani broad
sustain portfolio market-lead proprietari
pharmaceut biolog sold world-wide
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
humira imbruvica market product compar
current base case assumpt blue sky valuat base
dcf driven wacc termin valu
grey sky valuat base lower sale humira
imbruvica market product compar current base
case assumpt grey sky valuat base dcf driven
wacc termin valu
 close
follow-up
opportun speak member team follow
confer call gain addit clariti dynam around certain product
well bake updat expect around fy
summar compani answer question
 confirm net price benefit expect humira us
 see greater impact co-pay accumul program us
impact humira us volum
see expans program steadi state yoy
share pressur set newer agent particularli dermatolog
gi see faster switch tnf agent less cycl
tnf rheumatolog share mayb point yoy
gener share hold well
 ex-u humira distinguish impact price volum
major yoy oper due price
 ex-u humira provid visibl expect see biosimilar
competit ex-u sale countri face pressur
allud call
go major remain see biosimilar
countri like japan eros curv european countri
sale japan insignific amount
 upadacitinib detail view dose
submit data dose abbv recommend dose ra
pivot trial see statist significantli efficaci dose
vs humira dose show comfort dose
like indic drive differenti efficaci
noth problemat dose safeti perspect
submit fda late decemb
 pancreat ca clearli tough indic data indic chang
thought around potenti imbruvica solid tumor broadli
doesnt realli chang viewpoint sinc assign high po along
 hcvlonger term outlook guidanc suggest global sale
similar trend expect market next year
break us vs expect beyond
major factor patient treatment volum
overal market share exit global us
asp us slightli mix
eu mid-singl digit
market share somewhat steadi market share rel
earli
price stabil futur realm possibl two player
 risankizumab file impact govern shutdown
heard impact regard file
 sale breakdown formulari posit guidanc product
lower consensu
clear would slow ramp
tri fundament chang treat patient take time educ
littl lighter mayb time consensu expect seem reason
peak opportun
uterin fibroid file year help next year us
dtc advertis start help
expect exit coverag mid-year
limit ex-u opportun given reimburs dynam plan file
 threshold amount addit debt would will take
deal debt/ebitda ratio use guid
articul target regard debt
feel good debt level
gener lot cash
feel hamstrung anyway
 gm pushes/pul
humira roll product mix product measur help
partnership econom headwind
 remain commit target
feel good growth
feel good prospect
contribut share repurchas ep
gotten mani question investor ask us level ep
contribut due share repurchas ep guidanc analysi figur
compon compani guidanc suggest ep would
assum top-line growth respect arriv ep
guidanc midpoint would like repurchas share
equat current stock price per share
sale
figur contribut share repurchas ep
sale
oper growth less unfavor fx impact
expect bp improv gm
sale
sale
approach net interest expens
tax earn
tax rate
share count end
averag share
ep midpoint guidanc
ep contribut due
contribut compon gross margin expans
compani expect gross margin expand bp driven
reduct humira royalti bp product mix bp product
bp partial off-set dilut effect partnership account bp
estim bp gross margin expans would add ep
analysi assum flat top-line share repurchas estim
contribut factor lead gross margin expans figur
figur ep contribut compon gross margin expans
ep without bp gm benefit gm
contribut product
dilut partnership account
ep bp gm benefit gm
without expect bp gross margin benefit estim ep would
per share assum flat top-line growth share repurchas figur
figur ep without bp gross margin expans
sale
sale
tax earn
ep gm bp benefit
ep contribut
bp gm expans
oper growth less unfavor fx impact
expect bp improv gm
sale
sale
approach net interest expens
tax rate
share count end
averag share
ep lower guidanc share repurchas
estim contribut assum flat top-line
charl martineau pm univers toronto figur calcul compon gross margin expans
net sale y/i growth
contribut humira royalti
net sale y/i growth
contribut product
net sale y/i growth
benefit product
contribut product
dilut partnership account
net sale y/i growth
dilut impact partnership account
contribut product
us million except per share valu
us million unless otherwis state
fx impact sale
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
product sold ex-amort
tax earn
average share outstand
dilut ep oper
compani mention price
